Q1 saw 18% revenue growth, 20% EPS increase, and strong order intake with a book-to-bill above 1.1. Six acquisitions expanded the portfolio, especially in MedTech and the UK, while proprietary products rose to 80% of sales. Management remains confident amid positive market trends.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.